Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17M Buy
351,952
+112,374
+47% +$5.24M 0.14% 125
2025
Q4
$11.6M Buy
239,578
+48,049
+25% +$2.38M 0.11% 170
2025
Q3
$9.04M Buy
191,529
+64,398
+51% +$3.11M 0.09% 209
2025
Q2
$6.14M Buy
127,131
+111,571
+717% +$5.7M 0.07% 226
2025
Q1
$863K Buy
15,560
+1,994
+15% +$108K 0.01% 787
2024
Q4
$654K Sell
13,566
-792
-6% -$40.3K 0.01% 825
2024
Q3
$827K Buy
14,358
+956
+7% +$51.6K 0.02% 700
2024
Q2
$650K Buy
13,402
+145
+1% +$7K 0.02% 763
2024
Q1
$644K Sell
13,257
-4,315
-25% -$211K 0.01% 716
2023
Q4
$874K Buy
17,572
+899
+5% +$44K 0.02% 602
2023
Q3
$894K Buy
+16,673
New +$889K 0.03% 549

Other funds holding SNY

Vident Advisory's SNY Position: Q1 2026 in Review

Vident Advisory increased its Sanofi (SNY) stake by 47% in Q1 2026, buying an estimated $5.24M and bringing the position to 351,952 shares worth $17M. The position accounts for 0.14% of the portfolio, ranked #125.

Vident Advisory first reported a position in SNY in Q3 2023 and has held it in 11 quarters since. 737 funds tracked by Wall St. Rank hold SNY as of Q1 2026.

  • Vident Advisory held 351,952 shares of Sanofi worth $17M as of Q1 2026.
  • Vident Advisory bought 112,374 Sanofi shares in Q1 2026, an estimated $5.24M.
  • Sanofi made up 0.14% of Vident Advisory's portfolio in Q1 2026, its #125 holding.
  • Vident Advisory first reported a position in Sanofi in Q3 2023 and has held it in 11 quarters since.
  • 737 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.